Key Highlights
- Samuel C. Blackman, MD, PhD, joins Bonum Therapeutics as an independent director.
- Blackman is the co-founder of Day One Biopharmaceuticals and led the development of FDA-approved OJEMDA™ for childhood brain tumors.
- Blackman’s experience spans leadership roles at Merck, GlaxoSmithKline, and other biotech firms focused on cancer and immune-oncology therapies.
- Bonum Therapeutics leverages novel antibody-based mechanisms to create safer, highly active medicines.
Source: Business Wire
Notable Quotes
- “We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit Bonum and the patients Bonum is seeking to serve.” — John Mulligan, PhD, Founder & CEO at Bonum Therapeutics
- “The development of innovative therapeutics that have the potential to address ongoing gaps in both activity and safety for patients with a variety of life-threatening diseases has been core to my career as both a physician and drug developer. Bonum’s science, mission, team, and culture have made a significant impression on me, and I am excited to be a part of the company’s bright future.” — Samuel C. Blackman, MD, PhD, Independent Director at Bonum Therapeutics
SoHC's Take
The addition of Dr. Blackman to Bonum Therapeutics’ board marks a pivotal moment in the company’s trajectory. His extensive background in developing groundbreaking therapies, coupled with his leadership roles in leading biotech firms, positions Bonum to accelerate its efforts in creating safer, highly targeted medicines. This strategic move underscores Bonum’s commitment to bridging critical gaps in oncology and immune-oncology, while laying the groundwork for its innovative pipeline to enter the clinic.
